We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$260M
Cap. Flow
+$115M
Cap. Flow %
14.29%
Top 10 Hldgs %
40.15%
Holding
122
New
39
Increased
28
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17.4M
2
VERA icon
Vera Therapeutics
VERA
+$16.7M
3
ONC
BeOne Medicines Ltd
ONC
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$11.4M
5
KURA icon
Kura Oncology
KURA
+$10.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$41.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.8M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$18.9M
4
LIAN
LianBio American Depositary Shares
LIAN
+$16.9M
5
VKTX icon
Viking Therapeutics
VKTX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
101
DELISTED
Dynavax Technologies
DVAX
– –
-300,000
Closed -$4.19M
EYPT icon
102
EyePoint Inc
EYPT
$1.06B
– –
-109,900
Closed -$2.54M
EYPT icon
103
PUT
EyePoint Inc
EYPT
$1.06B
– –
-320,100
Closed -$7.4M
GPCR icon
104
CALL
Structure Therapeutics
GPCR
$3.34B
– –
-100,000
Closed -$4.08M
IFRX icon
105
InflaRx
IFRX
$268M
– –
-200,097
Closed -$326K
KALV
106
DELISTED
KalVista Pharmaceuticals
KALV
– –
-125,969
Closed -$1.54M
NBIX icon
107
Neurocrine Biosciences
NBIX
$17.4B
– –
-10,000
Closed -$1.32M
NUVB icon
108
Nuvation Bio
NUVB
$2.18B
– –
-250,000
Closed -$378K
PBYI icon
109
Puma Biotechnology
PBYI
$422M
– –
-202,349
Closed -$876K
PEN icon
110
Penumbra
PEN
$12.5B
– –
-7,500
Closed -$1.89M
RLAY icon
111
Relay Therapeutics
RLAY
$4.18B
– –
-300,000
Closed -$3.3M
FLNA
112
CALL
Filana Therapeutics
FLNA
$49.3M
– –
-121,000
Closed -$2.72M
VRDN icon
113
Viridian Therapeutics
VRDN
$2.05B
– –
-50,000
Closed -$1.09M
CBAY
114
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,090,441
Closed -$25.8M
LIAN
115
DELISTED
LianBio American Depositary Shares
LIAN
– –
-3,779,694
Closed -$16.9M
IMGN
116
DELISTED
Immunogen Inc
IMGN
– –
-1,404,608
Closed -$41.6M
ARAV
117
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-346,511
Closed -$42.9K
MRTX
118
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,049
Closed -$5.88M
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Affinity Asset Advisors held 122 positions worth $808M, up 48% from $548M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Affinity Asset Advisors deployed $115M of net new capital in Q1 2024, opening 39 new positions and adding to 28 existing holdings. Its largest new stake was Vera Therapeutics: 470,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $18.9M trimmed.

  • Affinity Asset Advisors's largest Q1 2024 buy was Vera Therapeutics: 470,000 shares worth $20.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q1 2024, an estimated $17.4M increase.
  • Affinity Asset Advisors's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $18.9M.
  • Affinity Asset Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $41.6M.
  • Affinity Asset Advisors's ten largest holdings make up 40% of its $808M portfolio in Q1 2024.
  • Affinity Asset Advisors opened 39 new positions and closed 27 in Q1 2024.
  • Affinity Asset Advisors's portfolio value rose 48% quarter-over-quarter to $808M.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.